EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐ LT phase 3, open‐label study

C Tziotzios, R Sinclair iD, A Lesiak, S Mehlis, M Kinoshita-Ise, A Tsianakas, X Luo, E H Law iD, R Ishowo-Adejumo, R Wolk, M Sadrarhami, A Lejeune

Journal of the European Academy of Dermatology and Venereology · 2025-06 · 39 (6) · 1152-1162

DOI: 10.1111/jdv.20526 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 23.01.2025. Verfasst von C Tziotzios und 11 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, King's College London, London, UK. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ALLEGRO‐LT is an ongoing, long‐term, open‐label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA).

Objectives

To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss.

Methods

ALLEGRO‐LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study. The de novo cohort results are reported here. Patients aged ≥12 years with AA and ≥25% scalp hair loss received a daily, 4‐week 200‐mg ritlecitinib loading dose, followed by daily 50‐mg ritlecitinib. Analyses are based on data up to the cut‐off (December 2022). Efficacy outcomes included proportions of patients achieving Severity of Alopecia Tool (SALT) scores ≤20 and ≤10, Patient Global Impression of Change (PGI‐C) score of ‘moderately improved’ or ‘greatly improved’ and eyebrow assessment (EBA) and eyelash assessment (ELA) response (≥2‐grade improvement from baseline or normal score in patients with abnormal baseline EBA/ELA).

Results

Mean (SD) ritlecitinib exposure among the 449 de novo patients enrolled was 728.7 (273.81) days. At Month 24 (as observed), 73.5% and 66.4% of patients achieved SALT score ≤20 and ≤10; 82.4% had PGI‐C response; 60.8% and 65.7% had EBA and ELA response. 86.1% of patients reported treatment‐emergent adverse events (AEs); most were mild or moderate in severity, with the most frequent being positive SARS‐CoV‐2 test (24.2%), headache (20.8%) and pyrexia (13.0%). Rates of serious AEs, severe AEs and treatment discontinuations were 4.9%, 6.0% and 6.5%, respectively. Herpes zoster infection occurred in six patients, serious infections in four, malignancies (excluding nonmelanoma skin cancer) in three and major adverse cardiovascular events in three.

Conclusions

In patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile with long‐term treatment. Clinical Trial Registration ClinicalTrials.gov NCT04006457.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultTreatment OutcomePyrimidinesPyrroles

Substanzen

PF-06651600PyrimidinesPyrroles

Autor:innen und Institutionen

  • St John's Institute of Dermatology, King's College London, London, UK.
  • Sinclair Dermatology, Melbourne, Victoria, Australia.
  • Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland.
  • Laboratory of Autoinflammatory Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland.
  • Division of Dermatology, Department of Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan.

ORCID-Profile: R Sinclair, E H Law

Förderung

  • Pfizer Inc
  • Pfizer

Zitieren

APA

Tziotzios, C., Sinclair, R., Lesiak, A., Mehlis, S., Kinoshita-Ise, M., Tsianakas, A., Luo, X., Law, E. H., Ishowo-Adejumo, R., Wolk, R., Sadrarhami, M., & Lejeune, A. (2025). Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐ LT phase 3, open‐label study. Journal of the European Academy of Dermatology and Venereology, 39(6), 1152-1162. https://doi.org/10.1111/jdv.20526

Vancouver

Tziotzios C, Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Tsianakas A, et al. Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐ LT phase 3, open‐label study. Journal of the European Academy of Dermatology and Venereology. 2025;39(6):1152-1162. doi:10.1111/jdv.20526

BibTeX
@article{Tziotzios2025,
  author = {Tziotzios, C and Sinclair, R and Lesiak, A and Mehlis, S and Kinoshita-Ise, M and Tsianakas, A and Luo, X and Law, E H and Ishowo-Adejumo, R and Wolk, R and Sadrarhami, M and Lejeune, A},
  title = {Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐ LT phase 3, open‐label study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {6},
  pages = {1152--1162},
  doi = {10.1111/jdv.20526}
}
Kostenlos starten →